Last reviewed · How we verify
Minirin
At a glance
| Generic name | Minirin |
|---|---|
| Also known as | Desmopressin acetate |
| Sponsor | Hormozgan University of Medical Sciences |
| Target | Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Hereditary factor VIII deficiency disease
- Nocturnal enuresis
- Partial Central Diabetes Insipidus
- Polyuria
- von Willebrand disorder
Common side effects
Key clinical trials
- DDAVP for Pituitary Adenoma (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency (NA)
- Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis (NA)
- NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
- Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome (PHASE2)
- Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE (PHASE3)
- DDAVP Effect by TEG6 in Cardiac Surgery
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minirin CI brief — competitive landscape report
- Minirin updates RSS · CI watch RSS
- Hormozgan University of Medical Sciences portfolio CI